Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 840 results for "new england journal of medicine"

Novartis new heart failure medicine LCZ696 cut cardiovascular ...

At the European Society of Cardiology congress and published simultaneously in the New England Journal of Medicine, Novartis revealed that its investigational heart failure medicine, LCZ696, Big News Network, 2 weeks ago
[x]  

53 images for new england journal of medicine

Asiaone, 2 weeks ago
Epoch Times, 1 month ago
French Tribune, 2 weeks ago
The New Age Online, 1 month ago
Drug Discovery and Development, 1 month ago
Newswise, 1 month ago
Forbes.com, 1 month ago
Drug Discovery and Development, 2 months ago
Bioscience Technology Online, 2 months ago
Examiner.com, 1 day ago
French Tribune

New breakthrough in prostate cancer treatment

A new study reported in the New England Journal of Medicine has revealed that testing of an abnormal protein in the blood could help in the identification of prostate cancer in case of men who cannot be helped by two new drugs. The name of this ...
 French Tribune2 weeks ago AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer  New England Journal of Medicine2 weeks ago Blood Test for 'Nicked' Protein Predicts Prostate Cancer Treatment Response  Infrosoft2 weeks ago
Times Live South Africa

E-cigarette is a 'gateway drug'

The findings, published in the New England Journal of Medicine, add to the debate about the risks and benefits of e-cigarettes, which deliver nicotine directly without burning tobacco. "With e-cigarettes, we get rid of the danger to the lungs and ...
 Times Live South Africa2 weeks ago E-cigarettes may promote illicit drug use and addiction  Jagran Post2 weeks ago E-cigarettes may be gateway to drug abuse  Consumer Reports1 week ago Smoking e-cigs may lead to drug addiction  ZeeNews.com2 weeks ago
[x]  
Reuters

GLAXOSMITHKLINE : New England Journal of Medicine and ERS publish positive results from GSK phase III studies of mepolizumab in patients with severe eosinophilic asthma

Issued:London UK - LSE announcement Results published today in the New England Journal of Medicine (NEJM) and presented at the European Respiratory Society (ERS) congress provide further data from the two pivotal Phase III asthma studies of ...
 4 Traders1 week ago CASAA: New claims that e-cigarettes are a gateway to cocaine use are junk science  Reuters2 weeks ago
[x]  

Samenvatting: Fase III FIRST® (MM-020 / IFM 07-01) onderzoek van REVLIMID® gepubliceerd in New England Journal of Medicine

SUMMIT, N.J.--( BUSINESS WIRE )--Fase III FIRST® (MM-020 / IFM 07-01) onderzoek van REVLIMID® (lenalidomide) plus dexamethasone bij nieuw gediagnosticeerde patiënten met multipel myeloom die geen kandidaat zijn voor ...
 Business Wire2 weeks ago CELGENE : Phase III FIRST MM-020/IFM 07-01 trial of REVLIMID lenalidomide plus dexamethasone in newly diagnosed multiple myeloma patients who are not...  4 Traders1 week ago Celgene's Combination Regimen For Multiple Myeloma Reaches Primary Endpoint  Bioresearch Online1 week ago Phase III FIRST trial results of REVLIMID® Plus Dexamethasone in newly diagnosed multiple myeloma patients published  Medical News Today1 week ago
[x]  
Med India

Risk of Recurrent Blockage of Brain Blood in Sickle Cell Anemia Children can be Reduced Through Regular Blood Transfusions

A new study published in the New England Journal of Medicine suggests that providing regular blood transfusions can prevent recurrent blockage of brain blood among children with sickle cell anemia. In the United States, approximately 100,000 people, primarily ...
 Med India1 month ago The Child or Adolescent with Elevated Blood Pressure  New England Journal of Medicine1 week ago Study Finds Stem Cell Transplantation can Treat Immune Deficiency in Children  Med India1 month ago

Celgene: Good Data But What About the Patent Challenges?

Phase-III trial data for Celgene's (CELG) revlimid was published in the New England Journal of Medicine, and while the data was unchanged from a previous release, UBS analyst Matthew Roden still considers it good news for the stock. He explains why: ...
 Wall Street Business Network2 weeks ago
[x]  
Nasdaq

Legalized Medical Marijuana: Could It Cure the Epidemic of Painkiller Overdoses?

But new research just published in the prestigious Journal of the American Medical Association ( JAMA ) suggests that recent moves to legalize the use of medical marijuana for pain management may help to reverse the tide of opioid drug overdoses.
 Nasdaq2 weeks ago A Doctor's Dilemma On Medicinal Marijuana  Media Awareness Project2 weeks ago

PARADIGM-HF: Is It Applicable to US Patients?

Hello. This is Ileana Piña, Associate Chief of Cardiology at Montefiore Einstein Hospital and Medical Center in the Bronx, New York. Today I am in the beautiful city of Barcelona at the European Society of Cardiology (ESC) Congress. More than ...
 General Medicine eJournal1 week ago
Seeking Alpha

Novartis' LCZ696: A New Paradigm For Heart Failure Treatment

Summary Results of the PARADIGM-HF trial showed excellent results for Novartis' novel heart failure medication, which promises to utterly replace ACE inhibitors and angiotensin receptor blockers for certain patients. With prevalence and incidence ...
 Seeking Alpha1 week ago Novartis LCZ696: 'New Wonder Drug' OR 'Old Paradigm With Reduced Side Effects'  Seeking Alpha1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - new england journal of medicine
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less